RegenXBio’s RGX-202: Promising DMD Therapy with Best-in-Class Potential and Strategic BLA Plans
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
Promising Initial Data and Favorable Regulatory Pathway Support Buy Rating for RegenXBio’s RGX-202 in DMD Treatment
Analyst Gena Wang from Barclays maintained a Buy rating on RegenXBio (RGNX – Research Report) and keeping the price target at $50.00.Don't Miss ...
BioSpace1d
Regenxbio Gears Up to Challenge Sarepta in DMD as Gene Therapy Advances to Pivotal Studies
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
FierceBiotech1d
After seeing improved muscle function in phase 1/2 trial, Regenxbio launches pivotal DMD study
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a webcast to discuss the AFFINITY DUCHENNE® pivotal program and new clinical data, including the first functional data from the ongoing ...
GlobalData on MSN22h
Regenxbio eyes 2026 filing for Duchenne muscular dystrophy gene therapy
Regenxbio has revealed plans to submit a biologics licence application (BLA) for RGX-202, its investigational gene therapy ...
What's Going On With REGENXBIO Shares Monday?
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
Yahoo Finance6d
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic ...
Brokerages Set REGENXBIO Inc. (NASDAQ:RGNX) PT at $35.64
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...
Mena FN6d
REGENXBIO To Host Webcast Discussing Pivotal Program And First Functional Data From The AFFINITY DUCHENNE® Trial Of RGX-202
including the first functional data from the ongoing Phase I/II study of RGX-202, the company's next-generation gene therapy for the treatment of Duchenne muscular dystrophy. The webcast will ...